Have a personal or library account? Click to login
Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease Cover

Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease

Tremor and Other Hyperkinetic Movements
Volume 10 (2020): Issue 0
By: Etienne Goubault,  Sarah Bogard,  Pierre J. Blanchet,  Erwan Bézard,  Claude Vincent,  Davide Martino,  Justyna Sarna,  Oury Monchi and  Christian Duval  
Open Access
|Jul 2020

References

  1. 1Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, et al. Cardinal Motor Features of Parkinson’s Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia. J Park Dis. 2018; 8(2): 323–31. DOI: 10.3233/JPD-181312
    Back to article
  2. 2Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Sarna J, Monchi O, Duval C. Remnants of cardinal symptoms of Parkinson’s disease, not dyskinesia, are problematic for dyskinetic patients performing activities of daily living. BMC Neurology UNDER REVIEW; 2018. DOI: 10.3389/fneur.2019.00256
    Back to article
  3. 3Duncan RP, Earhart GM. Measuring participation in individuals with Parkinson disease: Relationships with disease severity, quality of life, and mobility. Disabil Rehabil. 2011; 33(15–16): 1440–6. DOI: 10.3109/09638288.2010.533245
    Back to article
  4. 4Trail M, Petersen NJ, Nelson N, Lai EC. An exploratory study of activity in veterans with Parkinson’s disease. J Neurol. Août 2012; 259(8): 1686–93. DOI: 10.1007/s00415-011-6400-7
    Back to article
  5. 5Foster ER, Golden L, Duncan RP, Earhart GM. Community-based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson’s disease. Arch Phys Med Rehabil. Févr 2013; 94(2): 240–9. DOI: 10.1016/j.apmr.2012.07.028
    Back to article
  6. 6Hamed R, Holm MB. Psychometric properties of the Arab Heritage Activity Card Sort. Occup Ther Int. Mars 2013; 20(1): 23–34. DOI: 10.1002/oti.1335
    Back to article
  7. 7Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, et al. Remnants of Cardinal Symptoms of Parkinson’s Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Front Neurol [Internet]. 2019 [cité 22 Mars 2019];10. Disponible sur: https://www.frontiersin.org/articles/10.3389/fneur.2019.00256/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Neurology&id=444842. DOI: 10.3389/fneur.2019.00256
    Back to article
  8. 8Zach M, Friedman A, Sławek J, Derejko M. Quality of life in Polish patients with long-lasting Parkinson’s disease. Mov Disord Off J Mov Disord Soc. Juin 2004; 19(6): 667–72. DOI: 10.1002/mds.10698
    Back to article
  9. 9Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ, CARPA Study Group. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 3 Juin 2008; 70(23): 2241–7. DOI: 10.1212/01.wnl.0000313835.33830.80
    Back to article
  10. 10Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson’s disease: A systematic review. Parkinsonism Relat Disord. Janv 2011; 17(1): 1–9. DOI: 10.1016/j.parkreldis.2010.08.012
    Back to article
  11. 11Hung SW, Adeli GM, Arenovich T, Fox SH, Lang AE. Patient perception of dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. Oct 2010; 81(10): 1112–5. DOI: 10.1136/jnnp.2009.173286
    Back to article
  12. 12Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. Mars 1992; 55(3): 181–4. DOI: 10.1136/jnnp.55.3.181
    Back to article
  13. 13Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 24 Nov 2009; 73(21): 1738–45. DOI: 10.1212/WNL.0b013e3181c34b47
    Back to article
  14. 14Kim JI, Sunwoo MK, Sohn YH, Lee PH, Hong JY. The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson’s Disease. J Mov Disord. Sept 2016; 9(3): 152–9. DOI: 10.14802/jmd.16020
    Back to article
  15. 15Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. Août 2012; 27(9): 1125–8. DOI: 10.1002/mds.25070
    Back to article
  16. 16Yesavage JA, Sheikh JI. 9/Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version. Clin Gerontol. 18 Nov 1986; 5(1–2): 165–73. DOI: 10.1300/J018v05n01_09
    Back to article
  17. 17Katz N, Karpin H, Lak A, Furman T, Hartman-Maeir A. Participation in Occupational Performance: Reliability and Validity of the Activity Card Sort. OTJR Occup Particip Health. 1 Janv 2003; 23(1): 10–7. DOI: 10.1177/153944920302300102
    Back to article
  18. 18Opara JA, Brola W, Leonardi M, Błaszczyk B. Quality of life in Parkinson’s disease. J Med Life. 15 Déc 2012; 5(4): 375–81.
    Back to article
  19. 19Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes O-B. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism Relat Disord. Nov 2013; 19(11): 1027–32. DOI: 10.1016/j.parkreldis.2013.07.010
    Back to article
  20. 20Gazibara T, Pekmezovic T, Kisic Tepavcevic D, Svetel M, Tomic A, Stankovic I, et al. Health-related quality of life in patients with Parkinson’s disease: Implications for falling. Parkinsonism Relat Disord. Juin 2015; 21(6): 573–6. DOI: 10.1016/j.parkreldis.2015.03.007
    Back to article
  21. 21Jenkinson C. The SF-36 physical and mental health summary measures: an example of how to interpret scores. J Health Serv Res Policy. Avr 1998; 3(2): 92–6. DOI: 10.1177/135581969800300206
    Back to article
  22. 22Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. Mars 1996; 34(3): 220–33. DOI: 10.1097/00005650-199603000-00003
    Back to article
  23. 23Beuter A, de Geoffroy A, Edwards R. Analysis of rapid alternating movements in Cree subjects exposed to methylmercury and in subjects with neurological deficits. Environ Res. Janv 1999; 80(1): 64–79. DOI: 10.1006/enrs.1998.3885
    Back to article
  24. 24Duval C, Panisset M, Sadikot AF. The relationship between physiological tremor and the performance of rapid alternating movements in healthy elderly subjects. Exp Brain Res. 1 Août 2001; 139(4): 412–8. DOI: 10.1007/s002210100780
    Back to article
  25. 25Okada M, Okada M. A method for quantification of alternate pronation and supination of forearms. Comput Biomed Res Int J. Févr 1983; 16(1): 59–78. DOI: 10.1016/0010-4809(83)90007-1
    Back to article
  26. 26Duval C, Sadikot AF, Panisset M. Bradykinesia in patients with essential tremor. Brain Res. 18 Oct 2006; 1115(1): 213–6. DOI: 10.1016/j.brainres.2006.07.066
    Back to article
  27. 27Ghassemi M, Lemieux S, Jog M, Edwards R, Duval C. Bradykinesia in patients with Parkinson’s disease having levodopa-induced dyskinesias. Brain Res Bull. 15 Mai 2006; 69(5): 512–8. DOI: 10.1016/j.brainresbull.2006.02.015
    Back to article
  28. 28Daneault J-F, Carignan B, Sadikot AF, Duval C. Are quantitative and clinical measures of bradykinesia related in advanced Parkinson’s disease? J Neurosci Methods. 15 Oct 2013; 219(2): 220–3. DOI: 10.1016/j.jneumeth.2013.08.009
    Back to article
  29. 29Goubault E, Nguyen HP, Ayachi FS, Bogard S, Duval C. Do Bradykinesia and Tremor Interfere in Voluntary Movement of Essential Tremor Patients? Preliminary Findings. Tremor Hyperkinetic Mov N Y N. 2017; 7: 459. DOI: 10.5334/tohm.341
    Back to article
  30. 30Mann RK, Edwards R, Zhou J, Fenney A, Jog M, Duval C. Comparing movement patterns associated with Huntington’s chorea and Parkinson’s dyskinesia. Exp Brain Res. 1 Mai 2012; 218(4): 639–54. DOI: 10.1007/s00221-012-3057-0
    Back to article
  31. 31Chelaru MI, Duval C, Jog M. Levodopa-induced dyskinesias detection based on the complexity of involuntary movements. J Neurosci Methods. 30 Janv 2010; 186(1): 81–9. DOI: 10.1016/j.jneumeth.2009.10.015
    Back to article
  32. 32Fenney A, Jog MS, Duval C. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson’s disease dyskinesias and in Huntington’s chorea. Clin Neurol Neurosurg. Févr 2008; 110(2): 160–7. DOI: 10.1016/j.clineuro.2007.10.010
    Back to article
  33. 33Dai H, Zhang P, Lueth TC. Quantitative Assessment of Parkinsonian Tremor Based on an Inertial Measurement Unit. Sensors. 29 Sept 2015; 15(10): 25055–71. DOI: 10.3390/s151025055
    Back to article
  34. 34Rigas G, Tzallas AT, Tsipouras MG, Bougia P, Tripoliti EE, Baga D, et al. Assessment of tremor activity in the Parkinson’s disease using a set of wearable sensors. IEEE Trans Inf Technol Biomed Publ IEEE Eng Med Biol Soc. Mai 2012; 16(3): 478–87. DOI: 10.1109/TITB.2011.2182616
    Back to article
  35. 35Heida T, Wentink EC, Marani E. Power spectral density analysis of physiological, rest and action tremor in Parkinson’s disease patients treated with deep brain stimulation. J Neuroengineering Rehabil. 8 Juill 2013; 10: 70. DOI: 10.1186/1743-0003-10-70
    Back to article
  36. 36Duval C. Rest and postural tremors in patients with Parkinson’s disease. Brain Res Bull. 15 Juin 2006; 70(1): 44–8. DOI: 10.1016/j.brainresbull.2005.11.010
    Back to article
  37. 37Duval C, Panisset M, Strafella AP, Sadikot AF. The impact of ventrolateral thalamotomy on tremor and voluntary motor behavior in patients with Parkinson’s disease. Exp Brain Res. Avr 2006; 170(2): 160–71. DOI: 10.1007/s00221-005-0198-4
    Back to article
  38. 38Tsipouras MG, Tzallas AT, Rigas G, Tsouli S, Fotiadis DI, Konitsiotis S. An automated methodology for levodopa-induced dyskinesia: Assessment based on gyroscope and accelerometer signals. Artif Intell Med. Juin 2012; 55(2): 127–35. DOI: 10.1016/j.artmed.2012.03.003
    Back to article
  39. 39Lee SI, Daneault J-F, Golabchi FN, Patel S, Paganoni S, Shih L, et al. A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors. In: 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). 2015; 8087–90. DOI: 10.1109/EMBC.2015.7320270
    Back to article
  40. 40Mann RK, Edwards R, Zhou J, Jog M, Duval C. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson’s disease. Clin Neurol Neurosurg. Juin 2010; 112(5): 392–9. DOI: 10.1016/j.clineuro.2010.02.003
    Back to article
  41. 41Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother. 23 Août 2006; 7(13): 1715–30. DOI: 10.1517/14656566.7.13.1715
    Back to article
  42. 42Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord Off J Mov Disord Soc. Janv 2015; 30(1): 80–9. DOI: 10.1002/mds.26125
    Back to article
  43. 43Fox SH, Lang AE. Levodopa-related motor complications–phenomenology. Mov Disord Off J Mov Disord Soc. 2008; 23 Suppl 3: S509–514. DOI: 10.1002/mds.22021
    Back to article
  44. 44Verhagen Metman L, Espay AJ. Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease. Neurology. 15 2017; 89(7): e83–4. DOI: 10.1212/WNL.0000000000004238
    Back to article
  45. 45Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: Clinical manifestations. Mov Disord Off J Mov Disord Soc. 2005; 20 Suppl 11: S11–16. DOI: 10.1002/mds.20458
    Back to article
  46. 46Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord Off J Mov Disord Soc. Févr 2005; 20(2): 224–30. DOI: 10.1002/mds.20279
    Back to article
  47. 47Hechtner MC, Vogt T, Zöllner Y, Schröder S, Sauer JB, Binder H, et al. Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord. Sept 2014; 20(9): 969–74. DOI: 10.1016/j.parkreldis.2014.06.001
    Back to article
  48. 48Montel S, Bonnet A-M, Bungener C. Quality of Life in Relation to Mood, Coping Strategies, and Dyskinesia in Parkinson’s Disease. J Geriatr Psychiatry Neurol. 6 Janv 2009; 22(2): 95–102. DOI: 10.1177/0891988708328219
    Back to article
  49. 49Jasinska-Myga B, Heckman MG, Wider C, Putzke JD, Wszolek ZK, Uitti RJ. Loss of ability to work and ability to live independently in Parkinson’s disease. Parkinsonism Relat Disord. Févr 2012; 18(2): 130–5. DOI: 10.1016/j.parkreldis.2011.08.022
    Back to article
  50. 50Haahr A, Kirkevold M, Hall EOC, Ostergaard K. Living with advanced Parkinson’s disease: A constant struggle with unpredictability. J Adv Nurs. Févr 2011; 67(2): 408–17. DOI: 10.1111/j.1365-2648.2010.05459.x
    Back to article
  51. 51Martínez-Martín P, Valldeoriola F, Tolosa E, Pilleri M, Molinuevo JL, Rumià J, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord Off J Mov Disord Soc. Mars 2002; 17(2): 372–7. DOI: 10.1002/mds.10044
    Back to article
  52. 52Tan DM, McGinley JL, Danoudis ME, Iansek R, Morris ME. Freezing of gait and activity limitations in people with Parkinson’s disease. Arch Phys Med Rehabil. Juill 2011; 92(7): 1159–65. DOI: 10.1016/j.apmr.2011.02.003
    Back to article
  53. 53Dural A, Atay MB, Akbostanci C, Kucukdeveci A. Impairment, disability, and life satisfaction in Parkinson’s disease. Disabil Rehabil. 8 Avr 2003; 25(7): 318–23. DOI: 10.1080/0963828021000043761
    Back to article
  54. 54Dafsari HS, Reker P, Silverdale M, Reddy P, Pilleri M, Martinez-Martin P, et al. Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson’s Disease. Neuromodulation J Int Neuromodulation Soc. 20 Déc 2017. DOI: 10.1111/ner.12740
    Back to article
  55. 55Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson’s disease: The relative importance of the symptoms. Mov Disord. 30 Juill 2008; 23(10): 1428–34. DOI: 10.1002/mds.21667
    Back to article
  56. 56D’Iorio A, Vitale C, Piscopo F, Baiano C, Falanga AP, Longo K, et al. Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson’s disease. Parkinsonism Relat Disord. Oct 2017; 43: 114–7. DOI: 10.1016/j.parkreldis.2017.08.003
    Back to article
  57. 57Chaudhuri KR, Jenner P, Antonini A. Reply to: « Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens ». Mov Disord Off J Mov Disord Soc. 2019; 34(12): 1930–1. DOI: 10.1002/mds.27871
    Back to article
  58. 58Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, et al. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol. 2017; 24(12): 1532–8. DOI: 10.1111/ene.13466
    Back to article
  59. 59Jenkinson PM, Edelstyn NMJ, Stephens R, Ellis SJ. Why Are Some Parkinson Disease Patients Unaware of Their Dyskinesias?: Cogn Behav Neurol. Juin 2009; 22(2): 117–21. DOI: 10.1097/WNN.0b013e3181a722b0
    Back to article
  60. 60Sitek EJ, Soltan W, Wieczorek D, Robowski P, Schinwelski M, Slawek J. Assessing self-awareness of dyskinesias in Parkinson’s disease through movie materials. Funct Neurol. Sept 2011; 26(3): 121–6.
    Back to article
  61. 61Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA. Dyskinesia matters. Mov Disord Off J Mov Disord Soc. Mars 2020; 35(3): 392–6. DOI: 10.1002/mds.27959
    Back to article
  62. 62Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol Scand. Nov 2017; 136(5): 378–85. DOI: 10.1111/ane.12733
    Back to article
  63. 63Pilleri M, Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease. Expert Opin Drug Saf. Févr 2015; 14(2): 281–94. DOI: 10.1517/14740338.2015.988137
    Back to article
  64. 64Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet Lond Engl. 4 Mai 2002; 359(9317): 1589–98. DOI: 10.1016/S0140-6736(02)08520-3
    Back to article
  65. 65Daneault J-F, Carignan B, Sadikot AF, Panisset M, Duval C. Drug-induced dyskinesia in Parkinson’s disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med. 20 Mars 2013; 11(1): 76. DOI: 10.1186/1741-7015-11-76
    Back to article
DOI: https://doi.org/10.5334/tohm.403 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: May 20, 2020
Accepted on: May 25, 2020
Published on: Jul 8, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Parkinson’s disease,
Levodopa-induced dyskinesia,
Participation,
Every-day life,
Activity engagement

© 2020 Etienne Goubault, Sarah Bogard, Pierre J. Blanchet, Erwan Bézard, Claude Vincent, Davide Martino, Justyna Sarna, Oury Monchi, Christian Duval, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 10 (2020): Issue 0Next article